Heart team. When the oncologist should join? HTML

Authors: Barbarash О.L.

Company: Research Institute for Complex Issues of Cardiovascular Diseases, Sosnovyy bul’var, 6, Kemerovo, 650002, Russian Federation

Email: Log in or register.

Heading: Editorial article

UDC: 616.12-006
DOI: https://doi.org/10.24022/1997-3187-2018-12-2-95-99

For citation: Barbarash О.L. Heart team. When the oncologist should join? Creative Cardiology. 2018; 12 (2): 95–9 (in Russ.). DOI: 10.24022/1997-3187-2018-12-2-95-99

Received / Accepted:  May 10, 2018 / May 16, 2018

Key Words: comorbidity in cardiovascular disease chemotherapy-induced cardiotoxicity


The article presents novel insights into the management of patients with coexisting cardiovascular disease and can- cer. The most significant challenges of preparing patients with cardiovascular disease for non-cardiac (cancer) surg- eries are raised. The existing limitations on the diagnosis, prevention and treatment of chemotherapy-induced car- diotoxicity while treating malignant tumors are discussed. The prospects for future researches aimed at assessing the unified mechanisms of cardiovascular disease and cancer development are presented.

Acknowledgements. The study had no sponsorship.
Conflict of interest. The author declares no conflict of interest.


  1. Wotton R., Marshall A., Kerr A., Bishay E., Kal- kat М., Rajesh Р. et al. Does the revised cardiac risk index predict cardiac complications following elec- tive lung resection? Cardiothorac. Surg. 2013; 1(8): 220. DOI: 10.1186/1749-8090-8-220.

  2. Brunelli A., Ferguson M.K., Salati M., Vigneswa- ran W.T., Jimenez M.F., Varela G. Thoracic revised cardiac risk index is associated with prognosis after resection for stage I lung cancer. Ann. Thorac. Surg. 2015; 100 (1): 195–200. DOI: 10.1016/j.athoracsur.2015.03.103.

  3. Колоскова Н.Н., Шаталов К.В., Бокерия Л.А. Определение пикового потребления кислоро- да: физиологические основы и области применения. Креативная кардиология. 2014; 1: 48–57 / Koloskova N.N., Shatalov K.V., Bockeria L.A. Determination of peak oxygen consumption: physiological bases and fields of application. Creative Cardiology. 2014; 1: 48–57 (in Russ.)

  4. olchard S., Angell J., Pyke M., Lewis S., Dodds N., Darweish A. et al. Cardiopulmonary reserve as determined by cardiopulmonary exercise testing correlates with length of stay and predicts complications after radical cystectomy. BJU International. 2015; 115 (4): 554–61. DOI: 10.1111/bju.12895.

  5. West M.A., Asher R., Browning M., Minto G. Perioperative exercise testing and training society. Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery. British J. Surg. 2016; 103 (6): 744–52. DOI: 10.1002/bjs.10112.

  6. Kumar R., Garcea G. Cardiopulmonary exercise testing in hepato-biliary and pancreas cancer surgery. A systematic review: are we any further than walking up a flight of stairs? Int. J. Surg. 2018; 52: 201–7. DOI: 10.1016/j.ijsu.2018.02.019.

  7. Berkel A.M., Bongers B.C., van Kamp M.S., Kotte H., Weltevreden P., De Jongh F. et al. The effects of prehabilitation versus usual care to reduce postoperative complications in high-risk patients with colorectal cancer or dysplasia scheduled for elective colorectal resection: study protocol of a randomized controlled trial. BMC Gastroenterolology. 2018; 18 (1): 29. DOI: 10.1186/s12876-018-0754-6.

  8. Maeda H., Kanzaki M., Sakamoto K., Isaka T., Yamazaki K., Onuki T. Surgery for non-small cell lung cancer in patients with a history of cardiovascular surgery. Surg. Today. 2017; 47 (3): 284–92. DOI: 10.1007/s00595-016-1386-5.

  9. Kenigsberg B., Wellstein A., Barac A. Left ventricular dysfunction in cancer treatment. JACC: Heart Failure. 2018; 6 (2): 87–95. DOI: 10.1016/ j.jcht.2017.08.024.

  10. Scott J.M., Nilsen T.S., Gupta D., Lee W. Jones exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018; 137: 1176–91. DOI: 10.1161/CIRCULATIONAHA.117.024671.

  11. Hasin T., Gerber Y., Weston S.A., Jiang R., Killian J.M., Manemann S.M. et al. Heart failure after myocardial infarction is associated with increased risk of cancer. JACC. 2016; 68 (3): 272–3. DOI: 10.1016/j.jacc.2016.04.053.

  12. O’Leary N., Murphy N.F., O’Loughlin C., Tiernan E., McDonald K. A comparative study of the palliative care needs of heart failure and cancer patients. Eur. J. Heart Fail. 2009; 11: 406–12. DOI: 10.1093/eurjhf/hfp007.

  13. Selvaraj S., Bhatt D.L., Claggett B., Djoussé L., Claggett B., Chen J. et al. Lack of association between heart failure and incident cancer. JACC. 2018; 71 (14): 1501–10. DOI: 10.1016/j.jacc.2018.01.069.

  14. Amerini P., Canepa M., Anker M.S., Belenkov Y., Bergler-Klein J., Cohen-Solal A. et al. Cancer diagnosis in patients with heart failure epidemiolo- gy, clinical implications and gaps in knowledge. Eur. J. Heart Fail. 2018; 20 (5): 879–87. DOI: 10.1002/ejhf.1165.

  15. Ridker P.M., MacFadyen J.G., Thurem T., Everett B.M., Libby P., Glynn R.J. Effect of inter- leukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390 (1015): 1833–42. DOI: 10.1016/s0140-6736(17)32247-X.

About Authors

Ol'ga L. Barbarash, Dr Med. Sc., Professor, Corresponding Member of Russian Academy of Sciences, Director, orcid.org/0000-0002-4642-3610

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery